NASDAQ · Healthcare · Drug Manufacturers—General
Amgen Inc. (AMGN)
As of Sep 25, 4:00 PM ET, Amgen (AMGN) last traded at $414.61, up 2.11% on the day. Its TickerHum research score is 67/100 (above average). It reported revenue of $38.1B for the twelve months ending 2026-06-30, up 9.1% year over year, with a 30.0% operating margin.
Ratings
- Valuation: 69/100 — Strongest input: price / sales (ttm) 5.9x. Weakest: free-cash-flow yield 4.5 %.
- Growth: 67/100 — Strongest input: diluted eps growth (ttm, yoy) +31.6 %. Weakest: revenue growth (ttm, yoy) +9.1 %.
- Profitability: 90/100 — Strongest input: return on equity 74.8 %. Weakest: net margin 23.0 %.
- Financial health: 15/100 — Strongest input: current ratio 1.37. Weakest: long-term debt / equity 4.44.
- Momentum: 81/100 — Strongest input: 1-year return +51.9 %. Weakest: 6-month return +17.4 %.
- Attention: 57/100 — Strongest input: headlines in the last 7 days 36. Weakest: volume vs 3-month average 0.8x.
- Risk: 79/100 — Strongest input: max drawdown (1y) -16.6 %. Weakest: annualised volatility (1y) 29.5 %.
- Data confidence: 90/100 — Strongest input: latest financial period age (days) 60 d. Weakest: quote age (hours) 45 h.
Reported fundamentals
| Metric | Value | Period |
|---|---|---|
| Revenue | $38.1B | TTM ending 2026-06-30 · 10-Q |
| Revenue growth | 9.1% | TTM ending 2026-06-30 · 10-Q |
| Net income | $8.74B | TTM ending 2026-06-30 · 10-Q |
| Diluted EPS | $16.10 | TTM ending 2026-06-30 · 10-Q |
| Operating margin | 30.0% | TTM ending 2026-06-30 · 10-Q |
| Net margin | 23.0% | TTM ending 2026-06-30 · 10-Q |
| Free cash flow | $10.18B | TTM ending 2026-06-30 · 10-Q |
| Cash | $13.99B | as of 2026-06-30 · 10-Q |
| Long-term debt | $51.86B | as of 2026-06-30 · 10-Q |
| Debt / equity | 4.44 | as of 2026-06-30 · 10-Q |
Source: SEC EDGAR XBRL company facts (CIK 0000318154).
Compare Amgen with its closest competitors
- Amgen vs Gilead Sciences (AMGN vs GILD) — Same industry (Drug Manufacturers—General); market cap 0.83x; shares: oncology
- Amgen vs Pfizer (AMGN vs PFE) — Same industry (Drug Manufacturers—General); market cap 0.73x; shares: oncology
- Amgen vs Merck & Co. (AMGN vs MRK) — Same industry (Drug Manufacturers—General); market cap 1.6x; shares: oncology
- Amgen vs Bristol-Myers Squibb (AMGN vs BMY) — Same industry (Drug Manufacturers—General); market cap 0.57x; shares: oncology
- Amgen vs AbbVie (AMGN vs ABBV) — Same industry (Drug Manufacturers—General); market cap 2.1x; shares: oncology
Prices: Yahoo Finance (public) — Free public Yahoo Finance data. Prices may be delayed and are for information only.